# CJC-1295 / Order

> A network-routed reading of CJC-1295 — how the molecule, the trial program, and the regulatory mesh connect.

## Pages

- [CJC-1295 / Order — Network-routed reading of the GHRH-analog research record](/index.md): Independent network-topology summary of CJC-1295 (CJC-1295 with DAC): the 30-residue GHRH analog whose maleimide group binds albumin Cys34, producing a 5.8-8.1 day plasma half-life and sustained GH/IGF-1 elevation across days.
- [CJC-1295 reported effects, safety cautions, and evidence status](/effects.md): What people report using CJC-1295 in research communities, the documented safety cautions from clinical evidence, and the state of the evidence — organized as a navigable node in the CJC-1295 / Order research graph.
- [CJC-1295 / Research — Mechanism, trials, detection, and the published evidence graph](/research.md): The primary research record on CJC-1295: GHRH-receptor mechanism, Phase 1 pharmacokinetics, the terminated Phase 2 program, preserved GH pulsatility, and the analytical-chemistry literature driven by anti-doping detection.
- [CJC-1295 / Dosage — Research-context only, never a recommendation](/dosage.md): What CJC-1295 doses were actually administered in published preclinical and Phase 1/2 research, framed strictly as research-context. CJC-1295 is not approved for human use; this page does not provide dosing for any non-research use.
- [CJC-1295 / FAQ — Mechanism, dosing context, trials, detection, and status](/faq.md): Fifteen common questions about CJC-1295 answered with direct reference to the published research: how the DAC handle works, what the Phase 1 data showed, why Phase 2 stopped, how anti-doping testing detects it, and where the regulatory line sits.
- [CJC-1295 / References — Full citation graph with DOIs and primary-source links](/references.md): Complete citation list for the CJC-1295 evidence record: discovery and Phase 1 pharmacokinetics, the terminated Phase 2 trial (NCT00267527), GHRH-R signaling reviews, the analytical-chemistry literature driving anti-doping detection, and epidemiologic context.
- [CJC-1295 / About — Editorial method, entity, and the disclaimer in plain language](/about.md): CJC-1295 Order is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic, do not sell any product, and are not affiliated with any vendor.
- [CJC-1295 / Contact — Editorial correspondence, corrections, and citation requests](/contact.md): Contact CJC-1295 Order for editorial correspondence, citation corrections, source suggestions, or accessibility requests. We do not respond to product inquiries, dosing questions, or vendor referrals.